The first aim of this study was to systematically describe the expression of PD-L1 in benign prostatic hyperplasia (BPH), localized prostate cancer (PC), and CRPC using two anti-PD-L1 antibodies. This evidence concerns the gene CD274 and benign prostatic hyperplasia.